Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

First pivotal trial for panic disorder Rx

Nov. 20, 1996

Cephalon/Leo neurological disease collaboration

Nov. 20, 1996

Antimigraine drug from Vanguard to enter pivotal trials

Nov. 20, 1996

Peripheral opiate antihyperalgesic from Adolor in clinical trials

Nov. 20, 1996

SKB reports D3-selective antipsychotic agents

Nov. 20, 1996

Analgesic kappa-opioid agonists reported by Pfizer

Nov. 20, 1996

Daiichi discloses cerebroprotective agents

Nov. 15, 1996

IL-6 as a target for Alzheimer's disease drug design

Nov. 15, 1996

New MS treatment approved in Israel

Nov. 15, 1996

AutoImmune's MS therapeutic in final stages of development

Nov. 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...